HIV Drug Information on Triumeq

(abacavir + lamivudine + dolutegravir)

Courtey ViiV Healthcare


Triumeq  is single-pill, fixed dosed combination antiretroviral drug used in the treatment of HIV, comprised of abacavir, lamivudine and dolutegravir. Manufactured by ViiV Healthcare Co., Triumeq was approved by the U.S. Food and Drug Administration (FDA) on August 22, 2014 for use in patients with HIV who do not have a past or current history of resistance to integrase inhibitors, abacavir or lamivudine.

Triumeq is not yet recommended in persons under the age of 12 or weighing less than 88 lbs (40kg), although clinical trials are currently underway to investigate the safety and efficacy of the drug in these groups.

Clinical Research Highlights:

The Phase III SINGLE trial studied the combination of dolutegravir (an integrase inhibitor) with abacavir and lamivudine (both nucleoside reverse transcriptase inhibitors) and found that it was  superior to Atripla (tenofovir + emtricitabine + efavirenz), with a lower number of discontinuations due to adverse drug effects than . After 48 weeks, 2% of subjects on the Tivicay-based regimen discontinued treatment versus 10% of those receiving Atripla.

Further research published in August 2014 concluded that the combination of the three drugs in one pill had the same bioequivalence to taking the three drugs separately.

While the SAILING study conducted in 2013 established that the dolutegravir component in Triumeq remained active even when there was resistance to other integrase inhibitors (such as Isentress or elvitegravir), it would require a twice-daily dose in order to do so—something that the current Triumeq formulation cannot accommodate.

Pre-Treatment Screening Recommendations:

It is recommended that patients be screened for the presence of a genetic marker, the HLA-B*5701 allele, before the initiation of an abacavir-containing drug. Triumeq should not be initiated in patients carrying this allele due to the high risk of an abacavir hypersensitivity reaction.

Triumeq is not recommended for patients with a creatinine clearance of less than 50 mL/minute, an indication of renal (kidney) impairment. As such, renal function always be tested before initiation of therapy with Triumeq.

Drug Dosage and Administration:

Triumeq is formulated in an oral tablet comprised of abacavir 600mg, lamivudine 300mg, and dolutegravir 50mg. The recommended dosage is one pill daily, taken with or without food.

Triumeq is an off-white oblong tablet embossed on one side with "572 Tri."

Common Side Effects:

The most commonly noted side effects (occurring in 2% or less of cases) are:

  • Insomnia
  • Headache
  • Dizziness
  • Nausea
  • Fatigue

Drug Interactions or Incompatibility:

Tikosyn (dofetilide), used in the treatment of arrhythmia (irregular heartbeat), is contraindicated for use with Triumeq.

To avoid possible drug-drug interaction, advise your doctor is you are taking any of the following medications or supplements:

  • Anti-seizure medication: Trileptal (oxcarbazepine), Dilantin (phenytoin), Phenytek (phenytoin), Luminal (phenobarbital), or carbamazepine-based drugs such as Carbatrol, Equetro, Tegretol, Teril, or Epitol
  • Rifampin-based antibiotics: Rifadan, Rifater, Rifamate, Rimactane
  • Metformin-based diabetic medication: Fortamet, Glucophage, Glumetza, Riomet
  • St. John's Wort


Patients who experience an allergic reaction after starting Triumeq should contact their doctor immediately. Treatment should be stopped and medical treatment sought if a rash is accompanied by fever, muscle or joint pains, blisters or sores, redness or swelling of the eyes, swelling of the face or mouth, or breathing problems. Patients who have previously experienced a hypersensitive reaction to Triumeq should not be re-challenged with the drug after resolution of symptoms

Triumeq should be taken two hours before or six hours after taking aluminum- or magnesium-containing antacids or laxatives, iron supplements, calcium supplements, buffered medications, or Carafate (sucralfate) use in the treatment of duodenal ulcers.

Inform your doctor of any liver condition you may have before starting Tivicay. There may be an increased risk for liver problems in some, particularly for people with hepatitis B (HVB), hepatitis C (HCV), or a pre-existing liver dysfunction. Liver enzymes should be regularly monitored as part of a person's routine blood tests taking Tivicay.


ViiV Healthcare. "ViiV Healthcare receives FDA approval for Triumeq." London, England; press release issued 22 August 2014.

Walmsley S.; Antela, A.; Clumeck, N.; et al. "Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results - SINGLE (ING114467)." 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; September 9-12, 2012; Abstract H-556b.

Weller, S.; Chen, S.; Borland, J.; et al. "Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food." Journal of Acquired Immune Deficiency Syndrome. August 1,2014;66(4):393-398.

Cahn, P.; Pozniak, A.; Mingrone, H.; et al. "Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study." Lancet. August 24, 2013;382(9893):700-708.

Continue Reading